Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of COMP360 psilocybin in treatment-resistant depression
2023-505268-12-00Phase 3Authorised
- Sponsor
- COMPASS Pathways
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of COMP360 in treatment-resistant depression (TRD) (2 arms), sponsored by COMPASS Pathways. Primary endpoint: Primary: change in MADRS total score at Week 6 (25 mg vs 1 mg). Planned start Oct 2023; status: authorised.
02
Drugs
COMP360
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2023-505268-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505268-12-00.